Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

ClinicalTrials.gov ID: NCT05930210

Public ClinicalTrials.gov record NCT05930210. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703 GEL compared with vehicle control in subjects with Wagner Grade 1 to Grade 2 diabetic foot ulcers. Baseline target ulcer size (\<16 cm2 vs ≥16 cm2 ) will be included as a stratification factor. Subjects will be randomized 1:1 to receive ENERGI-F703 GEL or vehicle control using an interactive web response system for randomization to automatically assign a unique subject randomization number. Total duration of the study will be up to 31 weeks including Screening visit (approximately 2 to 3 weeks), double-blind dosing/observation phase (16 weeks), and a safety follow-up of 12 weeks after the last administration of study treatment.

Study identification

NCT ID
NCT05930210
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Enrollment
230 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 29, 2023
Primary completion
Dec 29, 2025
Completion
Mar 30, 2026
Last update posted
Oct 1, 2025

2023 – 2026

United States locations

U.S. sites
10
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
A and D Doctor Center Miami Florida 33135 Recruiting
Bioclinical Research Miami Florida 33155 Recruiting
Reliant Medical Research Miami Florida 33165 Recruiting
Advanced Medical Research Institute Miami Florida 33174-3201 Recruiting
New Horizons Research Palmetto Bay Florida 33176 Recruiting
IACT Health Columbus Georgia 31904 Recruiting
The Jackson Clinic PA Jackson Tennessee 38305 Recruiting
Mt. Olympus Medical Research Houston Texas 77095 Recruiting
Wasatch Clinical Research Salt Lake City Utah 84107 Recruiting
Salem Veterans Affairs Medical Center VAMC Salem Virginia 24153-6404 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05930210, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 1, 2025 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05930210 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →